Boston Scientific is releasing in the United States its DIRECTSENSE Technology for live monitoring of cardiac tissue during radiofrequency ablation procedures. The capability is designed for use on the company’s RHYTHMIA HDx Mapping System along with the INTELLANAV MiFi Open-Irrigated ablation catheter and it works by measuring the change in electrical impedance of the tissue around the catheter as it is being irradiated.
It is currently very difficult to create sufficient lesions that alleviate cardiac arrhythmias while also minimizing unnecessary damage to surrounding tissues. Physicians have to perform a good deal of estimation based on patient anatomy combined with previously acquired knowledge and experience in similar procedures. As such, too often there’s insufficient ablation or overablation, which either don’t resolve the cause of an arrhythmia or cause additional side effects.
“Knowing the change in impedance around the tip of the catheter provides unique information about local tissue characteristics and the development of the lesion,” said David J. Callans, M.D., professor of medicine at the Perelman School of Medicine, University of Pennsylvania, in a Boston Scientific announcement. “Unlike existing products on the market, the DIRECTSENSE Technology assists physicians in evaluating pre-ablation tissue health, while supporting better clinical understanding of how they are influencing that tissue to guide minimal, predictable ablation during a procedure.”
Some related study data from the announcement:
According to chronic data from the LOCALIZE clinical trial, a retrospective analysis of the DIRECTSENSE Technology presented by Ignacio Garcia-Bolao, M.D., director of cardiology and cardiovascular surgery, University of Navarra, Pamplona, Spain at Heart Rhythm Society 2020 Science, a local impedance decrease of ≥16.6 ohms with an inter-lesion spacing of ≤ 6mm showed a ≥ 98% positive predicative value of durable pulmonary vein block at three months in patients with paroxysmal atrial fibrillation (AF).
Product page: DIRECTSENSE Technology
more recommended stories
Ardena’s Expertise Helps New Treatment for Parkinson’s Disease
Ghent, Belgium 30 August 2021: Ardena,.
Inflatable Neurostimulator for Minimally Invasive Pain Control
Researchers at the University of Cambridge.
Quasiprobabilities Shed Light on Quantum Advantage
Quantum advantage is a hot topic,.
The Total Knockout: Towards Personalized Anesthesia
A team of researchers at the.
Localized Prostate Cancer Therapy: Interview with Shyam Natarajan, CEO of Avenda Health
Avenda Health, a medtech company based.
What innovations could shape the future of orthopaedics?
Lloyd Hines looks at how advances.
Bromelain Market to Exhibit Significant Incremental Dollar Opportunity During the Forecast Period
Derived from the pineapple plant, the.
High-Tech Contact Lenses May Replace Smart Phones
When Alexander Graham Bell brought us.
First Dedicated Pediatric and Neonatal Acute Dialysis Machine Released U.S.
Medtronic is releasing in the United.
ivWatch Monitors IV Placement Sites for Leakage, Now Cleared by FDA
ivWatch, a company based in Newport.